Positive News SentimentPositive NewsNASDAQ:COCP Cocrystal Pharma (COCP) Stock Price, News & Analysis $1.18 +0.04 (+3.86%) Closing price 03:59 PM EasternExtended Trading$1.22 +0.04 (+3.38%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cocrystal Pharma Stock (NASDAQ:COCP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cocrystal Pharma alerts:Sign Up Key Stats Today's Range$1.14▼$1.2550-Day Range$0.82▼$1.2452-Week Range$0.76▼$2.03Volume176,481 shsAverage Volume894,179 shsMarket Capitalization$22.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapeutics for serious and potentially life-threatening viral infections. The company uses structure-based drug design and other drug-discovery technologies to develop small-molecule candidates intended to target highly conserved viral replication proteins. Its development programs have focused on infections including influenza A and B, norovirus and coronaviruses. Cocrystal’s investigational pipeline has included CC-42344, an orally administered influenza A polymerase inhibitor, and programs targeting norovirus and other viral pathogens. These candidates remain under clinical or preclinical development and are not approved for commercial use. Cocrystal Pharma is based in Bothell, Washington, and has historically operated as a research-oriented biotechnology company serving global infectious-disease markets through its drug-development programs and collaborations. The company’s leadership has included Gary Wilcox as president and chief executive officer. As a clinical-stage company, Cocrystal’s operations are primarily centered on research, clinical development and potential partnering rather than the sale of marketed products.AI Generated. May Contain Errors. Read More Cocrystal Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreCOCP MarketRank™: Cocrystal Pharma scored higher than 23% of companies evaluated by MarketBeat, and ranked 817th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCocrystal Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Cocrystal Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cocrystal Pharma are expected to grow in the coming year, from ($0.65) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cocrystal Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.76% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 5.24.Change versus previous monthShort interest in Cocrystal Pharma has recently increased by 4.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentCocrystal Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $9,800.00 in company stock, which represents 0.0430% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,800.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.40% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions6.72% of the stock of Cocrystal Pharma is held by institutions.Read more about Cocrystal Pharma's insider trading history. Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COCP Stock News HeadlinesCocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and TreatmentSeptember 9, 2026 | globenewswire.comCOCP: $5 Million Private Placement with OPKO HealthAugust 20, 2026 | finance.yahoo.comWhitney Tilson: “A New Kind of Civil War Begins in Less Than 100 Days”President Trump says AI regulation will not stop what he calls the greatest economic engine in history, bigger than oil, gold, diamonds, or the internet. Meanwhile, The New Republic reports Republicans are eager to rein in AI ahead of the midterms. Whitney Tilson, the analyst CNBC once called The Prophet for calling the dot-com crash, the Bear Stearns and Lehman collapses, and the 2009 market bottom, says a new divide begins in 100 days with major implications for portfolios. Tilson lays out what he believes could separate winning and losing portfolios over the next six months.September 18 at 1:00 AM | Stansberry Research (Ad)Cocrystal Pharma strengthens board with antiviral expert appointmentAugust 19, 2026 | theglobeandmail.comCocrystal Pharma Adds Veteran Leader to Board of DirectorsAugust 18, 2026 | tipranks.comCocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsAugust 17, 2026 | finanznachrichten.deCocrystal Pharma Appoints Carol Brosgart, M.D. to Board of DirectorsAugust 17, 2026 | quiverquant.comQCocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsAugust 17, 2026 | globenewswire.comSee More Headlines COCP Stock Analysis - Frequently Asked Questions How have COCP shares performed this year? Cocrystal Pharma's stock was trading at $0.9790 at the beginning of 2026. Since then, COCP stock has increased by 20.9% and is now trading at $1.1840. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.06. The company earned $0.11 million during the quarter, compared to the consensus estimate of $0.11 million. When did Cocrystal Pharma's stock split? Shares of Cocrystal Pharma reverse split on the morning of Tuesday, October 11th 2022.The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE). Company Calendar Last Earnings8/13/2026Today9/18/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 COCP's financial health is in the Green zone, according to TradeSmith. COCP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:COCP CIK1412486 Webwww.cocrystalpharma.com Phone(786) 459-1831FaxN/AEmployees10Year Founded2004Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.83 million Net MarginsN/A Pretax Margin-3,011.51% Return on Equity-207.47% Return on Assets-123.33% Debt Debt-to-Equity RatioN/A Current Ratio1.24 Quick Ratio1.24 Sales & Book Value Annual Sales$330 thousand Price / Sales69.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book2.57Miscellaneous Outstanding Shares19,263,000Free Float11,673,000Market Cap$22.81 million OptionableNot Optionable Beta1.48 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:COCP) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersWhy This Small AI Company Holds 150 PatentsJeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
